Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure mounts on US FDA to address alleged persistent sexual dysfunction with Merck's hair loss drug

This article was originally published in Scrip

Executive Summary

As physicians call for the US FDA to address reports of persistent sexual dysfunction with Merck & Co's male-pattern hair loss drug Propecia (finasteride), the US Judicial Panel on Multidistrict Litigation in San Diego, California, has scheduled a 29 March hearing session that will determine if a number of individual law suits filed against the company should be "centralised" in one legal action.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel